🚨Trade Alert 🚨 MYNZ

🚨Trade Alert 🚨 MYNZ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ With Blockbuster Early Detection for Colorectal Cancer, MYNZ May Soon Give ColoGuard a Run for its Money! Greetings All, Despite significant progress, cancer continues to be the second-largest cause of death in the U.S. Unfortunately, [more than 1.9 million new cases of cancer]( are likely to be diagnosed in the U.S. alone this year and more than 600,000 deaths are expected from the disease. This is a fantastic time to take a look at the cancer-fighting space on Wall Street, especially as healthcare is often an inflation hedge. One company to take a very close look at right now is an under-the-radar NASDAQ small cap that is zooming in on the massive colon cancer market. In recent years this disease has been striking younger and younger adults and awareness has been increasing. The company is called Mainz Biomed N.V. (NASDAQ: MYNZ) and has developed such a game-changing diagnostic tool to fight this disease that it could catapult them into soon becoming a leading cancer-focused stock! Revenues have been mounting for the company, former executives from major pharma giants are climbing on board, and there has been exciting FDA feedback for their lead product ColoAlert.... AND… the stock currently carries [a $25 price target!]( That’s about a 260% increase from current levels! At the company’s 52-week high of $17.81, the upside potential is still over 150%! Additionally MYNZ has a STRONG BUY rating from [NASDAQ!]( ColoAlert rivals Cologuard, which many of you may be familiar with and have seen ads for. Exact Sciences Corporation (NASDAQ: EXAS) is the company behind Cologuard and is a little over $60 a share now. MYNZ may be trading at a premium right now at around $6 as it continues to commercialize its ColoAlert test... and with the focus on getting it into the U.S., it could be game over for Exact Sciences Corp.! ColoAlert is a non-invasive test that can be taken at home, with a rapid response of 92% specificity and 85% sensitivity. As cases of colorectal cancer continue to affect people, with now younger groups being diagnosed, Mainz Biomed B.V. (NASDAQ: MYNZ) may represent one of the biggest health stock opportunities in the market with its game-changing diagnostics test! [www.mainzbiomed.com]( Mainz Biomed B.V. NASDAQ: MYNZ SAVING LIVES THROUGHINNOVATIVE MOLECULARDIAGNOSTIC SOLUTIONS! Founded in Germany, Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company is aiming to become a leading provider of easy-to-use diagnostic solutions for patients around the world. COMPANY HIGHLIGHTS - MYNZ protects its intellectual property through trade secrets to control all critical reagents, processes and formulations. - ColoAlert Holds Potential as a Blockbuster Early Detection Test for Colorectal Cancer. - Designed for profitability, rapid commercial uptake, and broad consumer acceptance. - The company is also developing proprietary genetic testing methods for pancreatic cancer. Key Corporate & Product Development Highlights in 2022 include: - Accelerated international commercial activities for ColoAlert, the Company’s highly efficacious and easy-to-use detection test for colorectal cancer (CRC). - Appointed Darin Leigh, former Abbott and Luminex executive, as Chief Commercial Officer. - Established partnership with Dante Labs to market ColoAlert in Italy and the United Arab Emirates. - A high-profile partnerships with leading laboratory Labor MVZ Dr. Stein + Kollegen, commonly referred to as “Laboratory Mönchengladbach” (February), one of the largest diagnostics laboratories in Germany, servicing over 2,500 physicians, processing over five million samples annually and screening approximately 1,000 patients per week specifically for CRC. - Initiated and enrolled the first patient in an international clinical study (ColoFuture) evaluating the integration of novel mRNA biomarkers into ColoAlert – potentially upgrading its technical profile to achieve “gold standard” status for CRC at-home testing. - Received supportive feedback from the U.S. Food and Drug Administration (FDA) on ColoAlert’s pre-submission package for its U.S. pivotal clinical trial set to commence in Q4 2022. - Achieved multiple preclinical milestones supporting the continued development of PancAlert, a potential first-in-class screening test for pancreatic cancer. - Executed a $25.8 million (gross) public follow-on offering. - Expanded Strategic Advisory Board of global leaders in molecular diagnostic development and commercialization. [SOURCE]( COLOALERT The Company’s flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer. PATIENT KIT: SIMPLE, FAST, ACCURATE AND NON-INVASIVE Patients receive a simple kit that includes instructions, a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results. IT’S THAT EASY. While the product is not approved yet for the U.S., it may be in the future, and this could be a game changer considering that it needs smaller samples than rival Cologuard!ColoAlert Highlights - A PCR-based molecular genetic CRC early detection stool test - Up to 60% fewer missed cases compared to fecal immunochemical test (FIT) 10 - Non-invasive, no preparation or sedation, no time off work - 98% patient satisfaction – Easy product to use 11 - Designed to offer affordable CRC screening solutions 10 Comparing ColoAlert sensitivity with FITs (Gies et al. Gastroenterology 154/2018) 11 98% overall satisfaction with ColoAlert in our internal customer survey. ColoAlert is CE-IVD marked and is approved for sale in Europe. European sales provide near-term revenue potential, while MYNZ prepares their entry into the US market. An astounding 19 million colonoscopies are performed each year in the U.S. according to [iDataResearch.]( The ColoAlert has been Europe's answer to what the ColoGuard is in the U.S. and now the test is headed to the states. This could be monumental for the company! Colon Cancer Cases are Rising Colorectal cancer is the second leading cause of cancer death in the US according to Cancer.org. This is men and women combined! Recent FDA guidance recommends colorectal cancer screening for everyone over the age of 45, which translates to market potential of [over 52 million tests per year](. Significant Impact: Cancer.org has found that colorectal cancer is highly preventable; with early detection providing 5- year survival rates above 90%! Diagnoses of colorectal cancer (which includes colon and rectal cancer) also continue to increase among adults younger than 50. “We don’t understand a lot about the causes, the biology, or how to prevent early onset of the disease,” said Phil Daschner, a program director in NCI’s [Division of Cancer Biology](. “And that’s important to learn more about because it may affect [approaches for] the treatment and [survivorship]( of early-onset colon cancer.” Priority Rollout Markets - ColoAlert launches from Germany… to Europe and America - ▪ Expansion into EU markets is aligned with early-stage plans for American market entry. - ▪ Upon FDA approval, Mainz BioMed plans to offer ColoAlert CRC screening test kits to national reference labs and major health institutions in the USA. - ▪ Mainz BioMed is carefully evaluating FDA requirements to ensure an expedited strategy is aligned with future clinical, regulatory and related guideline requirements. - - ▪ Key clinical studies will be co-located in the US and abroad to meet the requirements set by FDA for a screening application COMPARABLE Exact Sciences, the makers of ColoGuard, offers the only other competitive product using similar technology. Other sector companies promote testing for CRC but are using standard tests like FIT or occult blood testing. Currently, Exact Sciences (NASDAQ: EXAS) has a market cap of about $11B! RECENT DEVELOPMENTS - [Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program]( - [Mainz Biomed Launches Corporate Health Program in Germany for ColoAlert]( - [Mainz Biomed Expands European Commercial Footprint and Enters Markets in Spain and UK]( - [Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert]( - [Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study]( THE BOTTOM LINE With every problem comes an opportunity -- in this case, a massive opportunity because cancer is a big problem. Both large and small companies are developing new ways of diagnosing and treating cancer and MYNZ may have one of the best ways to fight off colon cancer early on. With a blockbuster early detection test for colorectal cancer that could give Exact Science's Cologuard a run for its money... now is the time to be paying attention to emerging player MYNZ!The company's closest peer, Exact Sciences (NASDAQ: EXAS) - ColoGuard product is only sold in the US - and has a market cap of about $11 billion. TO REITERATE.... COLOALERT IS EASIER TO ADMINISTER AND MORE ACCURATE! ColoAlert Holds Potential as a Blockbuster Early Detection Test for Colorectal Cancer and Could Turn Mainz Biomed (NASDAQ: MYNZ) into One of the Biggest GROUND-FLOOR Success Stories on Wall Street! Start your research right away! Copyright 2022 © SCDalerts.com is owned and operated by the owner of SCD Media LLC. Disclaimer and Privacy For more Information please contact info@smallcapsdaily.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to SCD Alerts. SCD Alerts is a financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing “I” or “we” or “our” or “SCD” refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in MYNZ. We have been currently compensated up to Twenty Five Thousand Dollars Cash ($25,000) via bank wire transfer from a third-party ACN, LLC for a 1 Day Marketing Program regarding MYNZ with a start date of 3/31/2023. We have been previously compensated up to Twenty Five Thousand Dollars Cash ($25,000) via bank wire transfer from a third-party ACN, LLC for a 1 Day Marketing Program regarding MYNZ with a start date of 3/03/2023. SCD’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCD often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. No longer want to receive these emails? [Unsubscribe](. Small Caps Daily 1334 Northampton St Easton, PA 18042